Harpoon Therapeutics raises $70M Series C for T-cell engager therapies
The company is currently running a Phase I study in prostate cancer and plans to advance additional therapies into Phase I trials and IND-enabling studies next year.
The company is currently running a Phase I study in prostate cancer and plans to advance additional therapies into Phase I trials and IND-enabling studies next year.
Taiho Ventures' investment pool is increased by $250 million, to $300 million. The fund will primarily focus on drugs for treating cancers.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.